Scala Biodesign

Scala Biodesign is an Israeli computational protein design company that develops ScalaOS, a no-code SaaS platform enabling R&D teams to design high-performance proteins — enzymes, antibodies, and therapeutic proteins — in a single design cycle. Founded in 2022 by researchers from the Weizmann Institute of Science, the platform combines physics-based atomistic calculations, evolutionary analysis, and AI modeling to introduce multiple beneficial mutations at once, dramatically reducing iteration cycles and accelerating time-to-market. Scala's technology is trusted by nine of the world's top-20 pharmaceutical companies across biotherapeutics, industrial biomanufacturing, and vaccine development.